CD169(+) macrophages are critical for osteoblast maintenance and promote intramembranous and endochondral ossification during bone repair by Batoon, Lena et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CD169(+) macrophages are critical for osteoblast maintenance
and promote intramembranous and endochondral ossification
during bone repair
Citation for published version:
Batoon, L, Millard, SM, Wullschleger, ME, Preda, C, Wu, AC-K, Kaur, S, Tseng, H-W, Hume, DA, Levesque,
J-P, Raggatt, LJ & Pettit, AR 2017, 'CD169(+) macrophages are critical for osteoblast maintenance and
promote intramembranous and endochondral ossification during bone repair' Biomaterials. DOI:
10.1016/j.biomaterials.2017.10.033
Digital Object Identifier (DOI):
10.1016/j.biomaterials.2017.10.033
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Peer reviewed version
Published In:
Biomaterials
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
Accepted Manuscript
CD169+ macrophages are critical for osteoblast maintenance and promote
intramembranous and endochondral ossification during bone repair
Lena Batoon, Susan Marie Millard, Martin Eduard Wullschleger, Corina Preda, Andy
Chiu-Ku Wu, Simranpreet Kaur, Hsu-Wen Tseng, David Arthur Hume, Jean-Pierre
Levesque, Liza Jane Raggatt, Allison Robyn Pettit
PII: S0142-9612(17)30682-8
DOI: 10.1016/j.biomaterials.2017.10.033
Reference: JBMT 18315
To appear in: Biomaterials
Received Date: 16 June 2017
Revised Date: 6 September 2017
Accepted Date: 17 October 2017
Please cite this article as: Batoon L, Millard SM, Wullschleger ME, Preda C, Wu AC-K, Kaur S, Tseng
H-W, Hume DA, Levesque J-P, Raggatt LJ, Pettit AR, CD169+ macrophages are critical for osteoblast
maintenance and promote intramembranous and endochondral ossification during bone repair,
Biomaterials (2017), doi: 10.1016/j.biomaterials.2017.10.033.
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to
our customers we are providing this early version of the manuscript. The manuscript will undergo
copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please
note that during the production process errors may be discovered which could affect the content, and all
legal disclaimers that apply to the journal pertain.
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
1 
 
CD169+ macrophages are critical for osteoblast maintenance and promote 1 
intramembranous and endochondral ossification during bone repair 2 
 3 
Lena Batoon1 (BBiomedSc), Susan Marie Millard1 (PhD), Martin Eduard Wullschleger2,3,6 (MD, 4 
PhD, FRACS), Corina Preda4 (BSc/BComm, MBBS), Andy Chiu-Ku Wu1 (PhD), Simranpreet 5 
Kaur1,5 (MSc(Biotech)), Hsu-Wen Tseng1 (PhD), David Arthur Hume3,7 (PhD), Jean-Pierre 6 
Levesque1,3 (PhD), Liza Jane Raggatt1,3 (PhD) and Allison Robyn Pettit1,3 (PhD). 7 
 8 
1. Bones and Immunology Laboratory, Mater Research Institute-The University of Queensland, 9 
Translational Research Institute, Woolloongabba, Queensland, Australia 4102; 2. Gold Coast 10 
University Hospital, Southport, Queensland, Australia, 4215; 3. The University of Queensland, 11 
Faculty of Medicine, Herston, Queensland, Australia, 4092; 4. Redcliffe Hospital, Queensland 12 
Health, Redcliffe, Queensland, Australia, 4020; 5. The University of Queensland, Diamantina 13 
Institute, Translational Research Institute, Woolloongabba, Queensland, Australia 4102. 6. 14 
Griffith University, School of Medicine, Southport, Queensland, Australia, 4215. 7. The Roslin 15 
Institute and Royal (Dick) School of Veterinary Studies, University of Edinburgh, 16 
Roslin, Midlothian EH25 9PS, Scotland, UK 17 
 18 
Corresponding Author: Allison R Pettit. Mater Research Institute-UQ, Translational Research 19 
Institute, 37 Kent Street, Woolloongabba, QLD, 4102. Phone: +617 3443 7575, Email: 20 
allison.pettit@mater.uq.edu.au  21 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
2 
 
ABSTRACT 22 
Osteal macrophages (osteomacs) contribute to bone homeostasis and regeneration. To further 23 
distinguish their functions from osteoclasts, which share many markers and growth factor 24 
requirements, we developed a rapid, enzyme-free osteomac enrichment protocol that permitted 25 
characterization of minimally manipulated osteomacs by flow cytometry.  Osteomacs differ from 26 
osteoclasts in expression of Siglec1 (CD169).  This distinction was confirmed using the CD169-27 
diphtheria toxin (DT) receptor (DTR) knock-in model. DT treatment of naïve CD169-DTR mice 28 
resulted in selective and striking loss of osteomacs, whilst osteoclasts and trabecular bone area 29 
were unaffected. Consistent with a previously-reported trophic interaction, osteomac loss was 30 
accompanied by a concomitant and proportionately striking reduction in osteoblasts. The impact 31 
of CD169+ macrophage depletion was assessed in two models of bone injury that heal via either 32 
intramembranous (tibial injury) or endochondral (internally-plated femoral fracture model) 33 
ossification. In both models, CD169+ macrophage, including osteomac depletion compromised 34 
bone repair. Importantly, DT treatment in CD169-DTR mice did not affect osteoclast frequency 35 
in either model. In the femoral fracture model, the magnitude of callus formation correlated with 36 
the number of F4/80+ macrophages that persisted within the callus. Overall these observations 37 
provide compelling support that CD169+ osteomacs, independent of osteoclasts, provide vital 38 
pro-anabolic support to osteoblasts during both bone homeostasis and repair. 39 
 40 
Keywords: osteomac, macrophage, bone regeneration, fracture repair, bone formation, osteoblast  41 
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INTRODUCTION 42 
Fractures caused by either traumatic injury [1] or disease-induced skeletal fragility [2] impose a 43 
significant and growing [3] global health burden. Even when satisfactory bone repair is achieved 44 
using first-line orthopedic management, bone fracture causes loss of productivity, reduced 45 
functionality and increased mortality [4]. Fracture healing is protracted in approximately 10% of 46 
fracture cases which exhibit delayed union or non-union [5]. There is currently no broadly 47 
applicable acute fracture therapeutic, despite the demonstrated benefit of acute therapeutic 48 
intervention (INFUSE™) in open tibial fractures [6]. Improved understanding of fracture healing 49 
biology is needed to inform development of both pharmaceutical and/or biomaterial-based 50 
approaches to reinforce or recapitulate the true regenerative capacity of bone [7]. 51 
Fracture healing progresses sequentially through three interdependent and overlapping phases: 52 
inflammatory, anabolic and remodeling. Appropriate execution of events within the inflammatory 53 
phase is essential to successfully establishing bone healing [8-10] as it achieves assembly of a 54 
vascularized granulation tissue [11-14]. Mesenchymal condensation and bone anabolism initiate 55 
within the granulation tissue and the anabolic phase can progress via either endochondral and/or 56 
intramembranous ossification, with cell fate decisions influenced by the degree of fracture 57 
stability [15, 16]. The final remodeling phase involves coupled osteoclast-osteoblast activity to 58 
remove and remodel the temporary hard callus/woven bone into anatomically appropriate mature 59 
lamellar bone [15].  60 
Identification and characterization of the resident macrophage population within the specialized 61 
tissues lining bone (osteal macrophages, osteomacs) [17] refocused attention on macrophage 62 
contributions to bone biology. Osteomacs have been shown to support osteoblast maturation, 63 
maintenance and function [17-26]. Multiple macrophage subsets contribute to fracture healing 64 
during both the inflammatory and anabolic phases, regardless of the ossification mechanism used 65 
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[20, 21, 24, 25, 27, 28]. Fracture-associated tissues contain recruited and resident macrophage 66 
subsets and their population dynamics vary both between intramembranous- and endochondral-67 
mediated repair as well as longitudinally during progression of fracture healing [17, 27, 29]. 68 
Macrophages contribute to many of the processes needed for fracture repair induction, 69 
progression and resolution [29]. Moreover, they have important roles in immune responses to 70 
biomaterials. Macrophage depletion leads to inhibition of osteoinduction by bone grafting 71 
materials [30], further demonstrating their function in directing repair-associated osteogenesis. 72 
Therefore, macrophages represent an attractive therapeutic target to promote bone regeneration. 73 
One limitation of previous studies investigating macrophage contributions to bone formation and 74 
repair has been collateral impacts on osteoclasts (specialized bone resorbing cells [31]) arising 75 
from in vivo ‘macrophage’ depletion approaches [17, 18, 24, 27, 28, 32]. Macrophages and 76 
osteoclasts share progenitors (myeloid lineage), growth factors (notably macrophage colony-77 
stimulating factor, CSF1) and many molecular markers. Osteoclasts can be targeted with 78 
relatively high specificity without major impacts on macrophages (e.g. via osteoprotegerin, 79 
cathepsin K and calcitonin receptor based strategies) [33, 34]. However, commonly used 80 
‘macrophage’ depletion approaches including clodronate liposome [35], lysozyme M driven-cre 81 
recombinase [36] and Csf1r-promoter or antibody based approaches [17, 25, 27, 37] also directly 82 
deplete osteoclasts [26, 30, 38]. As osteoclasts have established roles in long bone growth via 83 
endochondral ossification [39] and during fracture repair [15] that likely extend beyond their 84 
bone resorption function [40], their co-depletion somewhat confounds interpretation of the 85 
experimental outcomes. Despite strategies to reduce/compensate for the impact of macrophage 86 
depletion approaches on osteoclasts [18, 27] and the fact that osteoclast-specific targeting does 87 
not ‘phenocopy’ macrophage depletion model outcomes [27, 28, 41, 42], there is still ambiguity 88 
about the relative contribution of these cells to bone repair.  89 
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This study aimed to improve characterization of the macrophage subsets involved in bone 90 
biology and to separate macrophage from osteoclast contributions to in vivo bone homeostasis 91 
and repair. Based on literature and gene expression database interrogation, cluster of 92 
differentiation 169 (CD169) is a cell surface antigen reported to be restricted to mature resident 93 
macrophages [43], including those present in the bone marrow (BM) [44], and absent from 94 
osteoclast progenitors [45]. Herein, we confirm that CD169 expression distinguishes osteomacs 95 
from osteoclasts in vitro and in vivo, and utilize selective depletion of CD169+ cells to achieve 96 
improved specificity in dissecting the functions of osteomacs in bone biology and repair.  97 
 98 
MATERIALS AND METHODS 99 
Experimental animals 100 
Animal experiments were approved by The University of Queensland Health Sciences Ethics 101 
Committee and performed in accordance with the Australian Code of Practice for the Care and 102 
Use of Animals for Scientific Purposes. C57Bl/6 (wild type, WT) mice were obtained from 103 
Australian Resources Centre (Canning Vale, Western Australia, AU) and MacGreen Csf1r 104 
promoter-green fluorescent protein (GFP) reporter transgenic (B6N.Cg-Tg(Csf1r-105 
EGFP)1Hume/J) mice [46], were maintained in-house. Heterozygous CD169+/DTR knock-in 106 
(Siglec1tm1(HBEGF)Mtka) mice [47] were originally sourced from Riken Bio Resource Centre 107 
(Yokohama, Kanagawa, Japan) and contain the human diphtheria toxin (DT) receptor (DTR) 108 
knocked into the murine CD169 (Siglec-1) locus. Experimental CD169+/DTR mice were generated 109 
by F1 crosses of CD169DTR/DTR males with either WT or MacGreen (C57BL/6 background) 110 
females. As the CD169DTR/DTR x MacGreen F1 cross is benign with respect to mouse phenotype, 111 
all F1 CD169+/DTR have been referred to throughout as ‘CD169-DTR’. All mice were housed 112 
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under specific pathogen-free conditions in the Translational Research Institute Biological 113 
Resource Facility, fed standard chow with ad libitum water access and simulated diurnal cycle.   114 
Enrichment of endosteal and periosteal cells 115 
Both endosteal and periosteal enrichment methods were rapid enzyme free approaches, 116 
minimizing impact on macrophage phenotype. Femora harvested from female and male 4-week 117 
old MacGreen mice were used for enrichment of periosteal cells as previously described [29]. For 118 
enrichment of endosteal cells, extraneous muscle, connective tissue and periosteum were stripped 119 
from dissected femora and central BM was extracted by a coring approach using insertion of a 120 
25G needle. This technique was evaluated as successful using standard histology (not shown). 121 
Endosteum was exposed by longitudinal and transverse cuts to the bone. Endosteal enriched cells 122 
were dislodged twice using a GentleMACS Dissociator tissue homogenizer with matching C 123 
tubes (Miltenyl Biotec, NSW, AU) on “m_speen_03” setting. Dislodged cells were washed twice, 124 
first with 4 mL and second with 3 mL 2% fetal calf serum (FCS) in phosphate buffered saline 125 
(PBS) and filtered using 40 um cell strainer.  126 
Depletion of macrophages in naive CD169-DTR mouse model 127 
Uninjured 8 to 10-week old male W  mice and CD169-DTR mice were randomly allocated to 128 
groups treated with vehicle (0.9% sodium chloride) or 10 µg/kg body weight of DT (MBL 129 
International Corporation, MA, USA) once daily via intra-peritoneal injection over 4 consecutive 130 
days. DT was prepared as previously described [48]. Bone tissues and BM were harvested 24 131 
hours after the last injection. 132 
CD169+ cell depletion in a tibial bone injury model 133 
Intramembranous-mediated bone repair mechanisms were assessed in 11 to 13-week old male 134 
mice that had a drill hole injury created in the left tibia as previously described [27, 49] but with a 135 
minor modification: defect was generated using a 0.85 mm drill bit attached to an electric drill 136 
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(RISystems, Davos Platz, CH). Animals were randomly allocated to vehicle or treatment groups. 137 
DT or vehicle treatment was initiated 1 day post-surgery and continued for 4 consecutive days as 138 
a daily injection. Tissues were collected 4 days post-injury (n = 4/group; inflammatory-anabolic 139 
transition) and 7 days post-injury (n = 6/group; peak anabolic phase) [27]. 140 
CD169+ cell depletion in the MouseFix-plated experimental femoral fracture model   141 
A clinically relevant femoral fracture model using an internally fixed flexible plate (MouseFix, 142 
RISystems, Davos Platz, CH) [50] that heals through periosteal callus formation via 143 
endochondral ossification was used as previously described [28]. Experimental fractures were 144 
created in 11 to 14-week old male mice. Animals were randomly allocated to vehicle (n = 4) or 145 
DT (n = 7) groups. DT or vehicle treatment was initiated 1 day post-surgery and continued for 4 146 
consecutive days as a daily injection. Tissues were collected 14 days post-surgery (peak early 147 
anabolic phase) [28]. 148 
Tissue collection 149 
BM from the right femora was collected for flow cytometry by flushing with a 5 mL syringe 150 
mounted with 27G needle and 2 x 5 mL of 2% FCS in PBS. Left hind limbs were dissected, 151 
fixed, decalcified and processed for immunohistological analysis as previously described [27].  152 
Flow cytometry 153 
Cell suspensions were generated with 2% FCS in PBS and then incubated with the appropriate 154 
antibody cocktail for 40 minutes in the dark and on ice with agitation. The myeloid antibody 155 
cocktail was made in Fc (fragment crystallizable antibody region) block and contained anti-156 
F4/80-Alexa647 (clone BM8; AbD Serotec, Kidlington, UK), anti-CD169-PE (clone 3D6.112; 157 
Biolegend, San Diego, CA, USA), anti-Lymphocyte antigen 6 complex locus G6D (Ly6G)-158 
PE/Cy7 (clone 1A8; Biolegend) and anti-CD115-biotin (clone AFS98; Biolegend). In some 159 
experiments the myeloid cocktail also included anti-vascular cell adhesion molecule 1 (VCAM1)-160 
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Pacific blue (clone 429; BD Biosciences, NJ, USA). The mesenchymal antibody cocktail 161 
contained anti-Ter119-biotin (clone Ter-119; Biolegend), anti-CD31-BV605 (clone 390; 162 
Biolegend), anti-Sca-1-PE/Cy7 (clone D7; Biolegend) and anti-CD51-PE (clone RMV-7; 163 
Biolegend). The antibody cocktail for detecting non-haematopoietic cells,  including osteoblasts, 164 
in enriched osteal and bone marrow preparations contained F4/80 (clone BM8; AbD Serotec), 165 
CD45-APCCy5 (clone 30-F11; Biolegend), CD11b-BV605 (clone M1/70; Biolegend), and 166 
CD169 (clone 3D6.112; Biolegend). The antibody cocktail to detect osteoclast precursors 167 
consisted of anti-B220-FITC (clone RA3-6B2; Biolegend), anti-CD3-FITC (clone 145-2C11; 168 
Biolegend), anti-Ter119-biotin (clone Ter-119; Biolegend), anti-CD115-biotin (clone AFS98, 169 
Biolegend), anti-F4/80-Alexa647 (clone BM8; AbD Serotec), anti-Ly6C-APCFire750 (clone 170 
HK1.4; Biolegend), and anti-CD169-PE (clone 3D6.112; Biolegend) [51, 52]. Cells were then 171 
washed and incubated with the secondary antibody Strepavidin-PE-CF594 for 30 minutes. Cells 172 
were washed, resuspended in 300 µL 2% FCS in PBS. Specificity of staining was determined by 173 
comparison to unstained cells and appropriate isotype control cocktails. Five minutes prior to 174 
analysis 5 µg/mL 7-amino actinomycin D (Life Technologies, CA, USA) was added to each tube 175 
to allow exclusion of dead cells. Cells were examined via flow cytometry on a CyAn flow 176 
cytometer (Beckman Coulter, Brea, CA) and data were analyzed using FlowJo version 10 (Tree 177 
Star Data Analysis Software). Analyses were performed on live (7AAD-) cells after cell 178 
aggregate exclusion. Low (lo) to intermediate (int) expression of either CD115 or GFP was used 179 
to segregate macrophages from monocytes due to lower expression of the Csf1r gene in 180 
macrophages. CD169+ macrophages/osteomacs were gated as F4/80+Ly6G-CD115lo-int/GFPlo-181 
intCD169+ cells. Osteoblasts were gated as Ter119-CD45-CD31-Sca1-CD51+ cells [53]. 182 
Conversion of gated population percent frequency to absolute cell number was achieved by a 183 
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standardized correction approach incorporating percent of live cells with total leucocyte count 184 
(Coulter AcT Diff Hematological Analyzer, Beckman and Coulter) per femoral BM. 185 
Immunohistochemistry 186 
Immunohistochemistry (IHC) was performed on deparaffinized and rehydrated sections with 187 
unconjugated primary antibodies against F4/80 (clone Cl:A3-1; rat anti-mouse; Novus 188 
Biological, CO, USA), collagen type 1 (Col1a1; polyclonal; rabbit anti-mouse; US Biological, 189 
Swampscott, MA, USA), osteocalcin (polyclonal; rabbit anti-mouse; Enzo Life Sciences, 190 
Farmingdale, NY, USA), or relevant isotype control antibodies (normal rat IgG2b (Biolegend, 191 
San Diego, CA, USA) and normal rabbit IgG (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, 192 
USA). Briefly, sections were blocked for endogenous peroxidase activity and subsequently 193 
underwent antigen retrieval. For anti-osteocalcin and anti-Col1a1 staining this was achieved by 194 
treating tissues with 0.1% trypsin (Sigma-Aldrich, St Louis, MO) in PBS and for anti-F4/80 195 
staining using microwave heat retrieval in 10 mM sodium citrate (pH 6.0). Non-specific antibody 196 
binding was blocked using appropriate serum cocktails for the secondary antibody or Background 197 
Sniper (Biocare Medical, Concord, CA). Primary antibodies were diluted in either Tris-buffered 198 
saline (osteocalcin and Col1a1) or Da Vinci Green Diluent (F4/80; Biocare Medical) and 199 
incubated with sections for 90 minutes. Sections were subsequently incubated with a biotinylated 200 
F(ab′)2 of species-matched secondary antibody: goat anti-rat or goat anti-rabbit (Santa Cruz 201 
Biotechnology) followed by HRP-conjugated streptavidin (Dako Agilent Pathology Solutions, 202 
Denmark). Diaminobenzidine was developed as per the manufacturer (Dako’s) instructions and 203 
all sections were counterstained with Mayer’s hematoxylin (Sigma-Aldrich). Specificity of 204 
staining was assessed in serial sections in the same staining run using matched concentrations of 205 
appropriate isotype control antibodies (for examples see Supplemental Figure 2A). Tartrate-206 
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resistant acid phosphatase (TRAP) was performed as previously described [54] and Safranin-O 207 
staining done via standard histological protocol. 208 
Staining was imaged using either a Vectra III Spectral scanner (PerkinElmer, Waltham, MA) and 209 
analyzed using inForm© Cell Analysis™ 2.2 software (PerkinElmer), or using Olympus BX50 210 
microscope and imaged via Olympus CellSens standard software 7.1 (Olympus, Tokyo, JP). 211 
Anti-F4/80 and anti-galectin-3 dual immunofluorescence staining was performed as previously 212 
described [29].  213 
Histomorphometric Methods 214 
All sections were de-identified and assessed in a blinded manner. When analyses were based on 215 
area of staining or intensity of staining, automated software based approaches were used to 216 
reduce or eliminate human bias. Depending on the software used, either a single fully automatic 217 
algorithm or matched analysis threshold settings were applied to all samples within an 218 
experiment. F4/80+ osteomac canopy and osteocalcin+ osteoblast surface on the endosteal surface 219 
were quantified in uninjured tibia using adapted histomorphometry as described previously [17]. 220 
A length of 4-6 mm of bone surface in the mid-metaphyseal to mid-diaphyseal endosteal surface 221 
of the posterior aspect of the tibia was examined per section. Number of F4/80+ cells were 222 
quantified by manual counting of positive cells in 0.09 ± 0.02 mm2 of femoral periosteum.  223 
For quantification of osteoclast frequency, area of TRAP staining, intensity of TRAP staining and 224 
trabecular bone area, tiled images (20x magnification) of metaphyseal trabecular bone from 225 
TRAP stained sections were collected. To quantify osteoclast frequency, percent surface of 226 
TRAP+ staining per bone surface was quantified using ImageJ software (National Institutes of 227 
Health, NIH, Bethesda, MD, USA). Approximately 11 mm of bone surface length was examined 228 
in each section. For quantification of trabecular bone area and area of TRAP staining, the 229 
iterative training process within inForm© Cell Analysis™ 2.2 software (PerkinElmer) was used 230 
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to develop an algorithm which could segment images of the metaphyseal region into bone and 231 
BM, and detect magenta TRAP staining, respectively. Area of trabecular bone was expressed as a 232 
percentage of the total area of the region quantified which was on average approximately 1 ± 0.17 233 
mm2. The iterative training process within NIS-Elements Basic Research 3.22.09 software 234 
(Nikon Instruments Inc., Melville, NY, USA) was used to develop an algorithm which detected 235 
the intensity of the magenta-colored TRAP staining in tissue samples. 236 
Tiled images of individual tibial injury sites (including inter-cortical injury zone and intra-237 
medullary injury zone) were collected from anti-Col1a1 antibody-stained sections. inForm© Cell 238 
Analysis™ 2.2 software (PerkinElmer) was again used to develop an algorithm which segmented 239 
images of the injury site into regenerative tissue (woven bone, osteoblasts, condensing 240 
mesenchyme), scar tissue (fibrous connective tissue), bone (cortical and old bone) and other 241 
tissue (cortical bone fragments, BM, vascular sinuses). The algorithm utilized staining intensity 242 
and distribution of both diaminobenzidine chromogen (Col1a1) and hematoxylin (nuclei) to 243 
achieve image segmentation. Area of the regenerative tissue and scar tissue were subsequently 244 
expressed as a percentage of the injury zone.  245 
For quantification of F4/80 staining in tibial injury samples, 20x magnification tiled images were 246 
collected and percent F4/80 staining area within the injury site was measured using ImageJ 247 
software (NIH). In femoral fracture samples, quantification of total callus area (within 1 mm 248 
distally and proximally from the osteotomy site) was performed on tiled images of the callus 249 
collected from Safranin-O stained sections using ImageJ.  250 
In sections stained for F4/80, positive cells within the granulation tissue and woven bone regions 251 
of the callus were manually counted and expressed as number of F4/80+ cells per mm2 using 252 
ImageJ.  253 
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For all histology-based quantification methods described above, each data point represents the 254 
mean of analyses at 3 sectional depths/sample that were at least 50 µm apart.   255 
Serum TRAP-5b Immunoassay 256 
Blood was collected at time of euthanasia of DT or vehicle-treated CD169-DTR and WT mice 257 
via cardiac puncture.  Blood samples were allowed to clot at room temperature for 15 minutes 258 
and centrifuged at 3000 g for 10 minutes at 24ºC. Supernatants were collected. Serum TRACP-5b 259 
activity was assayed using MouseTRAP Assay TRACP-5b ELISA kit (Immunodiagnostic 260 
Systems, Boldon, Tyne and Wear, UK) as per the manufacturer’s instructions.  261 
Statistical analyses 262 
Statistically significant differences were determined where appropriate using either a one-way 263 
ANOVA with Tukey’s post-test or two-tailed unpaired t-test in PRISM 5 (GraphPad Software, 264 
La Jolla, CA). A value of p < 0.05 was considered statistically significant.   265 
 266 
RESULTS 267 
Macrophages within enriched endosteal and periosteal cell preparations express the mature 268 
macrophage marker CD169  269 
Macrophage characteristics can be significantly altered by ex vivo isolation and manipulation 270 
[55]. Therefore we developed a rapid, digestion-free technique to enrich for endosteal and 271 
periosteal osteomacs using MacGreen mice. The approach was verified by examining enrichment 272 
of osteoblasts (gated as per details in Materials and Methods and Supplemental Figure 1A) which 273 
should be abundant in periosteum and endosteum. Endosteal and periosteal preparations had a 2-274 
fold and 22-fold higher frequency of Ter119-CD45-CD31-Sca1-CD51+ osteoblasts [53] 275 
respectively compared to central BM (Figure 1A). By inference, these preparations should also be 276 
enriched for osteomacs over other central marrow resident macrophage populations [56]. 277 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
13 
 
The mouse transcriptional atlas data available at www.biogps.org [57] includes multiple 278 
macrophage, osteoclast and osteoblast profiles from ex vivo cultures produced in our laboratories. 279 
This data set confirmed the highly restricted expression of Siglec1, encoding CD169, in mouse 280 
macrophages, with minimal expression in osteoclast cultures (which contain ‘contaminating’ 281 
mononuclear cells including macrophages) and no expression in osteoblasts (data not shown). 282 
Assessment of siglec1 mRNA expression in primary murine osteoblasts, osteoclasts, bone 283 
marrow-derived macrophages and bone marrow mesenchymal stromal cells confirmed expression 284 
of siglec1 is restricted to macrophages within these relevant cell populations (Supplemental 285 
Figure 1B). Monoclonal anti-mouse CD169 antibodies are not indicated for paraffin embedded 286 
tissues and were not useful for determination of CD169 expression in situ. Therefore we 287 
investigated CD169 expression by flow cytometry in macrophages within enriched osteal tissue 288 
preparations, which by inference contain a high proportion of osteomacs. Resident macrophages, 289 
gated as F4/80+Ly6G-VCAM1+GFPlow-mid (Figure 1B, left and middle panels), were present in 290 
both the endosteal and periosteal enriched cell preparations and approximately 40% of these 291 
expressed CD169 (Figure 1B, right panel, and C). Non-hematopoietic cells (Figure 1D, includes 292 
mesenchymal and endothelial cells) as well as hematopoietic osteoclast precursors/progenitors, 293 
gated as per previously published and characterized [51, 52] (Figure 1E), within these cell 294 
preparations expressed minimal to no CD169.   295 
CD169+ osteomacs are required for osteoblast maintenance in vivo 296 
To confirm CD169 expression by osteomacs in vivo and secondary impacts of CD169+ 297 
macrophage depletion on osteoblasts, we utilized the CD169-DTR knock-in mouse model. DT 298 
was delivered as previously described [48] and cells and tissue collected as indicated in the 299 
schematic in Figure 2A. To control for CD169 haploinsufficiency in CD169-DTR mice (i.e. 300 
knock-in model), vehicle-treated WT and CD169-DTR mouse control groups were included. To 301 
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control for potential non-DTR transgene toxicity of DT, WT mice were treated with the same DT 302 
regimen.  303 
To gauge the depletion efficiency of the DT treatment protocol, the impact on bone marrow 304 
F480+Ly6G- cell number, which includes macrophages and monocytes is shown in Figure 2B. 305 
This broader myeloid gating was used as a first pass assessment to clarify whether any population 306 
reductions demonstrated using CD169 expression dependent gating were biased by reduced 307 
CD169 expression as a consequence of Siglec1 haploinsufficiency in CD169-DTR mice. DT 308 
treatment of WT mice did not impact on F4/80+Ly6G- cell frequency supporting minimal off 309 
target toxicity of the DT treatment. Interestingly, saline-treated CD169-DTR mice had 310 
significantly lower F4/80+Ly6G- frequency compare to saline WT, suggesting there was an 311 
impact of Siglec1 haploinsufficiency on BM monocyte/macrophage frequency. When compared 312 
to all other groups, F4/80+Ly6G- cells were significantly depleted in DT treated CD169-DTR 313 
mice (Figure 2B). Within the F4/80+Ly6G- gate, the relative proportion of 314 
CD11b+CD115/GFPhigh monocytes increased 4-fold (16.4 ± 2.3% versus 68.9 ± 8.9% in vehicle 315 
versus DT treated CD169-DTR mice respectively), an anticipated outcome based on lack of 316 
CD169 expression by monocytes. Overall, DT treatment in CD169-DTR mice induced selective 317 
depletion of F4/80+Ly6G- mature myeloid cells while preserving BM monocytes, further 318 
exemplifying the specificity of this macrophage depletion model.  319 
There was profound loss of CD169+ BM resident macrophages (F4/80+Ly6G-CD115loCD169+) in 320 
DT-treated CD169-DTR mice compared to all control groups (Figure 2C, p < 0.001). As this 321 
mirrored the observations in Figure 2B where cell population gating was not dependent on 322 
CD169, the observed depletion is unlikely to be contributed to by reduced CD169 immuno-323 
reactivity. Similar to F4/80+Ly6G- cells, Siglec1 haploinsufficiency was associated with a 324 
significant reduction in CD169+ BM resident macrophage number (Figure 2C, WT-vehicle versus 325 
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CD169-DTR-vehicle mice). There was no off target toxicity of DT on BM CD169+ resident 326 
macrophage number (Figure 2C, WT-vehicle compared to WT-DT treated).  327 
The impact of four sequential doses of DT was examined in situ using IHC in hind limb sagittal 328 
sections from the same experimental cohorts of WT and CD169-DTR mice used in Figure 2B-C. 329 
Anti-F4/80 antibody staining in combination with anatomical location was used to distinguish 330 
osteomacs [17]. In all control groups, F4/80+ macrophages were abundant in the central marrow 331 
(Figure 2D(i-iii)). F4/80+ endosteal osteomacs were observed on resting bone surfaces (not 332 
shown) and forming canopy-like structures over sites of active bone modelling (Figure 2D(i-iii), 333 
red arrows). Serial sections stained with anti-osteocalcin confirmed that these canopy osteomacs 334 
were adjacent to cuboidal osteocalcin+ osteoblasts lining the bone surface (Figure 2D(v-vii), 335 
black arrows), as previously reported [17]. DT treatment in CD169-DTR mice greatly reduced 336 
the number of F4/80+ central marrow macrophages (Figure 2D(iv)). Importantly, F4/80+ 337 
osteomacs and osteocalcin+ osteoblasts were rarely observed on endosteal bone surfaces in DT 338 
treated CD169-DTR mice (Figure 2D(iv and viii)). Loss of periosteal F4/80+ osteomacs was 339 
evident in both metaphyseal (not shown) and diaphyseal regions (Figure 3A-D). Osteomac loss 340 
was evident after one dose of DT (Figure 3A) whilst the endosteal osteoblast surface was not 341 
appreciably impacted until 3 doses of DT had been administered (Figure 3D).  342 
These observations were verified by histomorphometry [17]. In the endosteum, DT treatment 343 
alone and Siglec1 haploinsufficiency both resulted in small off-target impacts on the amount of 344 
endosteal bone surface that had associated osteomac coverage (Figure 3E). Siglec1 345 
haploinsufficiency was also associated with a 24% reduction in endosteal osteoblast surface 346 
(Figure 3F). Strikingly, DT treatment in CD169-DTR mice produced almost complete loss of 347 
F4/80+ endosteal osteomacs (Figure 3E, p < 0.001) which was accompanied by a 92% reduction 348 
of osteocalcin+ osteoblast-covered bone surface (Figure 3F, p < 0.001). No difference in 349 
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periosteal F4/80+ macrophage number was observed between the control groups (Figure 3G), 350 
indicating that Siglec1 haploinsufficiency and toxin off-target impacts are negligible in this 351 
tissue. Whereas profound loss of F4/80+ periosteal osteomacs occurred in DT-treated CD169-352 
DTR mice compared to all control groups (Figure 3G, p < 0.001).  353 
TRAP+ multinucleated osteoclasts were abundant in tibial metaphyseal bone of WT and CD169-354 
DTR mice irrespective of treatment (Figure 4A-D). As expected based upon the lack of CD169 in 355 
BM osteoclast precursors (Figure 1D) and Siglec1 mRNA in osteoclasts (Supplementary Figure 356 
1B), there was no difference between the percent area of TRAP+ surface/bone surface (Figure 357 
4E), percent area of TRAP staining within the metaphyseal region (Figure 4F) and TRAP 358 
staining intensity (Figure 4G) between DT-treated CD169-DTR mice and the control groups. 359 
While serum TRAP-5b activity was unexpectedly increased in DT-treated CD169-DTR mice 360 
(Figure 4H) compared to all control groups, there was no difference in trabecular bone area 361 
within the metaphyseal region (Figure 4I), suggesting that the treatment regimen did not alter 362 
osteoclast resorption activity. Consequently, assessment of total bone volume, bone mineral 363 
density and/or dynamic histomorphometry was not undertaken as in situ data indicated that the 364 
DT protocol used did not cause bone loss. Moreover, while the DT treatment regimen did result 365 
in dramatic loss of osteoblast surface, this was only evident within the final 24 hr of the 366 
experimental time course and therefore was unlikely to have had sufficient time to impact bone 367 
volume. Within the bone and marrow environment, the data support selective depletion of 368 
macrophages, including osteomacs in the CD169-DTR model. Of specific relevance, bone 369 
marrow monocytes and osteoclasts were not affected. 370 
CD169+ osteomacs are required for normal bone repair via intramembranous ossification 371 
To assess the functional contribution of CD169+ osteomacs to bone repair we used a previously 372 
validated tibial injury model that primarily heals via intramembranous ossification, forming 373 
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woven bone that bridges the injury site [27, 49]. To determine the impact of CD169+ macrophage 374 
loss during granulation tissue formation, DT or vehicle delivery was initiated 1 day post injury in 375 
CD169-DTR mice and repeated for the following 2 days. Tissues were harvested at day 4 post-376 
injury (Figure 5A). This treatment regimen resulted in a significant reduction in F4/80+Ly6G- 377 
cells (Figure 5B) and CD169+ macrophages (Figure 5C) in the contralateral femur BM of DT-378 
treated CD169-DTR mice, confirming efficacy of the DT regimen within each experimental 379 
animal. The percent area of F4/80+ staining within the injury site was reduced in DT-treated 380 
compared to vehicle-treated CD169-DTR mice (Figure 5D). In vehicle-treated CD169-DTR 381 
mice, F4/80+ macrophages were: 1) abundant in adjacent BM; 2) dispersed throughout the injury 382 
site associated granulation tissue; and 3) accumulated at the peripheral injury zone (Figure 5E). In 383 
the DT-treated CD169-DTR mice F4/80+ macrophages were: 1) greatly reduced in the adjacent 384 
BM; 2) rare within the granulation tissue; and 3) present, but at reduced frequency, in the 385 
peripheral injury zone (Figure 5F).  386 
To examine impact of CD169+ macrophage depletion on woven bone deposition, DT or vehicle 387 
delivery was again initiated 1 day post injury in WT and CD169-DTR mice and sustained for 4 388 
days (Figure 6A). Tissues were harvested 7 days post injury, which represents the peak anabolic 389 
phase with full bridging of the defect site with woven bone in WT mice [27]. At day 7 post 390 
injury, despite 3 days respite from DT treatment, substantial depletion of the contralateral limb 391 
BM CD169+ macrophages (Figure 6B, p < 0.001) and a parallel reduction of the total 392 
F4/80+Ly6G- macrophage/monocyte pool (Figure 6C, p < 0.001) were maintained in DT-treated 393 
CD169-DTR mice.  394 
DT treatment impacts on macrophages and Col1a1+ woven bone deposition within the injury site 395 
were assessed in situ (Figure 6D-I) using the same experiment cohort represented in Figure 6B-C. 396 
In vehicle-treated CD169-DTR mice, F4/80+ macrophages were abundant within adjacent BM 397 
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(Figure 6D, asterisk) and intercalated within the injury site forming canopy-like structures over 398 
Col1a1+ woven bone surfaces (Figure 6E-F). Although sustained profound BM CD169+ 399 
macrophage depletion was demonstrated in the contralateral limb in DT-treated CD169-DTR 400 
mice (Figure 6B and C), F4/80+ macrophages were detected within the injury site (Figure 6G), 401 
but the percent area of F4/80 staining, a surrogate of cell number [27], was significantly reduced 402 
compared to controls (Figure 6J). In control mice the injury-associated F4/80+ macrophages 403 
displayed elongated osteomac morphology and were distributed within the woven bone bridge 404 
(Figure 6D-F). Double immunofluorescence staining indicated these macrophages were a mix of 405 
galectin-3+ and galectin-3dim/- cells (Figure 7), as previously reported [27]. In contrast, 406 
macrophages within DT-treated CD169-DTR mice were predominantly of ramified inflammatory 407 
macrophage morphology (Figure 6H) but were negative for the inflammatory marker galectin-3 408 
(Figure 7) [58, 59].  409 
Col1a1 deposition in the injury site of DT-treated CD169-DTR mice was reduced compared to 410 
controls (Figure 6F and I), and when present, had mixed morphological characteristics with some 411 
areas resembling woven bone while others resembled fibrotic tissue (Figure 6I, Supplemental 412 
Figure 2B). A reduction in woven bone and increase in fibrotic tissue was confirmed in DT-413 
treated CD169-DTR mice by algorithm based segmentation of the injury site into regenerative 414 
tissue and fibrotic tissue (Supplemental Figure 2B and Figure 6K). DT treatment in wild type 415 
mice (ie. off-target DT toxicity) had no impact on F4/80+ macrophage number within the injury 416 
site and Col1a1 deposition (Supplemental Figure 3A-C). Quantitative (Figure 6L) and qualitative 417 
(Supplemental Figure 4A-B) examination of TRAP staining in metaphyseal trabecular bone of 418 
the injured limb indicated no difference in osteoclast frequency between the groups. TRAP+ 419 
osteoclasts were also readily detected in association with the injury site irrespective of treatment, 420 
but were not quantified as outcomes would be confounded by differences in the bone 421 
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regenerative response in DT-treated versus control CD169-DTR mice (Supplemental Figure 3C-422 
F).  423 
CD169+ osteomacs are required for optimal fracture healing via endochondral ossification 424 
The requirement for CD169+ osteomacs/macrophages in callus formation via endochondral 425 
ossification was tested using an internally plated (MouseFix) femoral fracture model [28, 50, 60-426 
63]. Femoral fractures were generated in WT and CD169-DTR mice and DT or vehicle were 427 
administrated for 4 days, initiating 1 day post-surgery, and tissue was collected at day 14 (Figure 428 
8A).  429 
Callus formation progression in vehicle-treated CD169-DTR mice was as expected for tissues 430 
collected at the peak of the early anabolic phase, largely consisting of a soft cartilaginous callus 431 
that was being progressively remodeled and replaced by woven bone (hard callus, Figure 8D).  432 
DT treatment in wild type mice had no impact on F4/80+ macrophage number within the 433 
granulation tissue and woven bone, and on callus size (Supplementary Figure 3D-E) indicating 434 
minimal fracture repair toxicity of the employed DT regimen.  Robust depletion of F4/80+Ly6G- 435 
myeloid cells (Figure 8B) and CD169+ BM macrophages (Figure 8C) was sustained in the 436 
contralateral limb of DT-treated compared to vehicle-treated CD169-DTR mice, even though 437 
tissues were collected 10 days after the last DT dose. Surprisingly, F4/80+ cells were detected 438 
within the injured limb BM via in situ IHC (data not shown) indicating potential variation in 439 
macrophage recovery dynamics in the injured limb. F4/80+ macrophages within the periosteal-440 
like tissue encapsulating the maturing callus were also observed in all mice (Figure 8F-G). 441 
However, callus formation in DT-treated CD169-DTR mice was stunted as shown by a 442 
significant decrease in overall size (Figure 8D-H). In all vehicle-treated CD169-DTR mice, 443 
F4/80+ osteomacs were abundant in woven bone forming at the periphery of the maturing soft 444 
callus (Figure 8D and F). Woven bone was absent from calluses in 3 out of 7 DT-treated CD169-445 
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DTR mice (data not shown). There was a significant reduction in the number of F4/80+ cells/mm2 446 
within total callus granulation tissue and woven bone of DT-treated versus vehicle-treated 447 
CD169-DTR mice (Figure 8I). Overall, CD169+ osteomac/macrophage depletion had 448 
significantly impaired bone healing via periosteal callus formation (Figure 8H, p < 0.01). 449 
Within the CD169+ macrophage-depleted experimental group, variation in the magnitude of 450 
fracture repair was observed (Figure 8H, range: 0 – 2 mm2 total callus area). Some animals 451 
exhibited minimal-small callus formation in which granulation tissue still predominated (Figure 452 
8G) whereas others had calluses that morphologically resembled control calluses but were 453 
appreciably smaller (not shown). These differences likely reflected biological variation in 454 
CD169+ macrophage depletion and/or recovery kinetics. Interestingly, a positive correlation 455 
between F4/80+ macrophage frequency in the callus and total callus size was observed (r = 0.9, p 456 
≤ 0.001, Figure 8J) when all mice were examined, recapitulating prior observations using 457 
alternative macrophage depletion approaches [28].  458 
 459 
DISCUSSION 460 
There is increasing recognition of the importance of macrophages in tissue repair processes [64], 461 
particularly in organs such as liver [65] and bone [28] that undergo a regenerative response. 462 
When added to macrophage contributions to innate immunity, particularly foreign body reactions 463 
[66, 67], carefully considered and targeted manipulation of macrophage function will be needed 464 
when developing biomaterial approaches for tissue repair. However, controversy persists relating 465 
to the role of macrophages in bone formation and regeneration. This in part originated from the 466 
historical misconception that macrophages within the bone microenvironment primarily represent 467 
a transient maturation stage in osteoclastogenesis, and this has been perpetuated by limitations 468 
associated with available ‘macrophage’ depletion models. These limitations include: 1) 469 
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unsatisfactory specificity of targeting macrophages versus other myeloid lineage cells, 470 
particularly osteoclasts; 2) variation in macrophage depletion magnitude depending on delivery 471 
route and/or delivered regimen of depletion triggering mechanism; and 3) that systemic depletion 472 
is generally induced. Herein we developed a minimal manipulation strategy to achieve osteal 473 
tissue enrichment and subsequently used a multiplexed flow cytometry approach to characterize 474 
osteomac cell-surface phenotype. Both endosteal and periosteal osteomacs expressed the highly 475 
restricted mature macrophage marker CD169. Of particular benefit, we provided in vivo evidence 476 
that expression of CD169 permitted positive selection/depletion of macrophages with 477 
exclusion/preservation of osteoclasts. Specifically we demonstrated that: in vitro generated 478 
osteoclast cultures had negligible expression of siglec1 mRNA, confirmed that osteoclast 479 
precursors do not express CD169 [45] and showed that CD169-targeted cell depletion had no 480 
negative effects on mature osteoclast number, size, TRAP expression intensity or bone resorption 481 
activity. In contrast, CD169-targeted cell depletion resulted in rapid and profound loss of both 482 
periosteal and endosteal osteomacs. Importantly the latter was accompanied by a striking 483 
reduction in endosteal osteoblasts.  484 
While we have demonstrated the potential benefits of the CD169-DTR model as an experimental 485 
tool for studying osteomac/macrophage contributions to bone biology and pathology, this model 486 
still has limitations. Although CD169 expression is highly specific to macrophages, it is not 487 
osteomac restricted. In lymphoid organs CD169 is expressed by specific subpopulations of 488 
resident macrophages with reported roles in immune regulation and tolerance [68]. Some resident 489 
macrophages within colon, kidney and liver have also been demonstrated to express CD169 [68]. 490 
Within bone and BM, use of the CD169-DTR model facilitated identification of hematopoietic 491 
stem cell (HSC) niche [44] and erythroid island [48, 69] macrophages. Indeed, CD169+ 492 
macrophage depletion impacts on the HSC niche may have delayed knock-on effects on 493 
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osteoclasts and other central marrow macrophages, irrespective of their CD169 expression status, 494 
via disruption of precursor supply [26, 44]. While this caveat had minimal impact on the 495 
experiments reported herein (i.e. monocyte pool was unperturbed), it could become a 496 
confounding factor in long time course experiments. On the flip side, not all BM, endosteal or 497 
periosteal macrophages (F4/80+Ly6GnegGFP/CD115loVCAM-1+) expressed CD169 and 498 
consequently were not depleted in the CD169-DTR model. While this confirms refined targeting 499 
precision within the multidimensional macrophage pool, compensatory mechanisms likely come 500 
into play, especially given macrophage plasticity and potential rapid maturation from recruited 501 
monocytes that were also maintained in this model. Available anti-mouse CD169 antibodies are 502 
not indicated for use in paraffin embedded tissues and we were unable to develop a validated 503 
anti-CD169 immunohistochemistry protocol. Reliance on anti-F4/80 immunohistochemistry to 504 
assess the impact of CD169+ cell depletion did somewhat reduce analysis precision. Overall, we 505 
have demonstrated the benefits of using CD169-DTR mice for dissection of bone biology and 506 
pathological mechanisms, however, as for all macrophage depletion model, careful experimental 507 
design and interpretation is still warranted.  508 
Even though hind limb osteoclast number, size, TRAP staining intensity characteristics and 509 
trabecular bone volume were unaltered, increased serum TRAP activity was observed following 510 
CD169+ macrophage depletion. Based on the collective data, it is unlikely that this observation 511 
reflects an actual increase in osteoclast activity, although we cannot rule out that osteoclast 512 
activity was increased at other skeletal sites not examined herein. An alternative explanation is 513 
that CD169+ macrophage phagocytic function within the bone microenvironment is responsible 514 
for clearance of excess TRAP produced during resorption events. Demonstration of close 515 
association of F4/80+ osteomacs to TRAP+ osteoclast at bone resorption sites, including within 516 
basic multicellular units [70], as well as presence of TRAP activity within phagocytic vesicles 517 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
23 
 
with F4/80+ macrophages [27] support this interpretation. While it is well known that 518 
macrophages, through production of inflammatory cytokines, can drive osteolytic responses in 519 
pathology [66], further investigation is required to determine whether macrophages, particularly 520 
osteomacs, have specific secondary support roles during bone resorption associated with bone 521 
growth and homeostasis.  522 
The impact of CD169+ osteomac depletion on the in vivo maintenance of endosteal osteoblasts 523 
irrefutably confirmed conclusions using less refined macrophage targeting strategies regarding 524 
the importance of osteomacs in supporting bone formation [17, 18, 25, 27]. Osteoblast loss was 525 
subsequent to osteomac depletion and is unlikely to be a specific bystander effect of induced-526 
osteomac death, as each of the experimental models achieves this outcome through highly varied 527 
death mechanisms (e.g. Fas-mediated apoptosis in Mafia mice, inhibition of mitochondrial 528 
ADP/ATP translocase by clodronate loaded liposomes versus inhibition of protein synthesis 529 
induced by DT). Hematopoietic stem cell mobilizing regimens of granulocyte colony stimulating 530 
factor also caused osteomac loss and subsequent osteoblast loss, with osteomac egress from BM 531 
implicated as the mechanism rather than osteomac death [26]. The magnitude of the osteoblast 532 
loss suggests that osteomacs either produce a required survival factor or that they support 533 
osteoblast maintenance through multiple mechanisms that culminate in essential symbiosis. 534 
Identification of these mechanisms is the next frontier for osteomac research and will be 535 
facilitated by the technical advances reported herein.   536 
CD169+ osteomac depletion impaired bone regeneration, irrespective of the ossification 537 
mechanism. The impact of CD169+ osteomac depletion initiated at the time of surgery on bone 538 
regeneration was not as pronounced as broad spectrum macrophage depletion initiated with the 539 
same timing, instead resembling outcomes of delayed broad spectrum depletion [27, 28]. 540 
Specifically, in Mafia mice callus formation was completely abolished after ‘macrophage’ 541 
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depletion initiated at the time of fracture. Whereas in DT-treated CD169-DTR mice, callus 542 
formation still initiated in all but one mouse, however these calluses were significantly smaller. 543 
Differences in the degree of healing between the depletion models could be interpreted in two 544 
ways. First, that CD169+ osteomacs have a lesser role in the inflammatory phase of bone repair. 545 
Second, their role in bone repair initiation can be at least partially compensated for by CD169- 546 
macrophages but that CD169+ macrophages become more critical as healing progresses toward 547 
the anabolic phase. These nuances will be difficult, but potentially important to dissect 548 
experimentally. They do not detract from the overall conclusion being that macrophages 549 
including CD169+ osteomacs play key roles in successful progression of bone healing. 550 
An intriguing observation was that in the tibial defect model, depletion of CD169+ 551 
osteomacs/macrophages changed the balance between bone regeneration versus fibrosis, favoring 552 
the latter. In normally healing tibial injuries, a mix of galectin-3+ and galectin-3- osteomacs were 553 
abundant within the injury site where they were associated with osteoblasts and woven bone 554 
surfaces particularly in the inter-cortical region. Galectin-3 is highly expressed on pro-healing 555 
alternatively activated macrophages [58, 59]. Moreover, F4/80+galectin-3+ macrophages are 556 
present at the metaphyseal corticalization zone in growing mice, which is a site of complex bone 557 
dynamics regulating cortical bone lengthening [29]. When bone repair was compromised due to 558 
CD169+ osteomac/macrophage depletion, galectin-3- macrophages predominated in the injury 559 
site. This suggests that depletion of CD169+ macrophages has specifically reduced the number of 560 
pro-regenerative macrophages within the injury site which conforms to the herein observed 561 
increase in fibrotic scar tissues within tibial injury sites. The observations highlight that the 562 
appropriate functional subset of macrophages is required to achieve the desired regenerative 563 
outcomes which will be an important consideration for therapeutic and/or biomaterial approaches 564 
designed to enhance bone repair [66]. More in-depth understanding of phenotype and molecular 565 
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profiles of pro-bone healing macrophages and what environmental inputs promote the functional 566 
maturation is needed to better inform design of bone healing interventions.  567 
In conclusion, we have provided direct evidence that CD169+ osteomacs, independent of 568 
osteoclasts, provide vital pro-anabolic support to osteoblasts during bone homeostasis and repair. 569 
The CD169-DTR model provides a unique experimental tool for differentiating the functional 570 
contributions of osteomacs and osteoclasts in bone biology and the development of therapeutic 571 
and biomaterial approaches to enhance bone repair. This model will facilitate further 572 
investigations into the role of osteomacs during the remodeling phase of bone repair and whether 573 
macrophages contribute to osteoclast biology. Finally, perturbations in osteomac/macrophage 574 
functional contributions and resultant changes to the reparative inflammatory process should be 575 
considered as a potential primary underlying mechanism for delayed healing and non-union 576 
outcomes in bone fractures.  577 
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Figure legends 799 
Figure 1. CD169 is expressed by endosteal and periosteal macrophages but not by 800 
osteoblasts and osteoclast precursors.  801 
A-C) Flow cytometry analysis of enriched endosteal and periosteal cell preparations from long 802 
bones of MacGreen mice. A) Fold increase in CD51+ osteoblast frequency in endosteal and 803 
periosteal cell preparations compared to total BM. B) Percent of CD169+ cells within the 804 
enriched resident macrophage populations in endosteal and periosteal cell preparations. C) 805 
Enriched resident macrophage were gated as F4/80+Ly6G-VCAM1+GFPlow-mid cells (left panel 806 
red gate and then subsequently middle panel blue gate). Expression of CD169 (right panel, blue 807 
line) within the resident macrophage gate (n = 9). Black lines in right panel show matched 808 
isotype control staining.  D) Non-hematopoietic cells in enriched bone marrow (BM) and 809 
periosteal preparations were gated as F4/80-CD45-CD11b-GFP- (panels left and middle). CD169 810 
expression in these cell populations (right panel, blue line) with black lines representing the 811 
matched isotype control. E) Osteoclast precursors/progenitors were gated as B220-CD3-Ter119-812 
CD115+F4/80-Ly6C+ (left panel. Expression of CD169 in this cell population (middle panel) and 813 
a fluorescence minus one (FMO) control (right panel). Data represents mean ± standard deviation 814 
of 2 biological repeats and a total of 4 independent samples (each sample represents a pool of 2-3 815 
mice). 816 
Figure 2. CD169+ macrophage depletion resulted in loss of osteomacs and osteoblasts on 817 
endosteal bone surfaces in naïve mice.  818 
A) Schematic representing the experimental design including DT/vehicle injection regimen and 819 
tissue harvest. B-C) Flow cytometric analysis of F4/80+Ly6G- myeloid cell (B, F+G- cells) and 820 
F4/80+Ly6G-CD115lowCD169+ macrophage (C, CD169+ cells) frequency in femoral BM at the 821 
experimental end point in wild type (WT) and CD169-DTR (DTR) mice treated with vehicle 822 
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(DTRx -) or DT (DTRx +). Significance was determined using one-way ANOVA with Tukey’s 823 
post-test. *, p<0.05; **, p<0.01; ***, p<0.001. Error bars represent standard deviation. D) 824 
Representative images of IHC staining for F4/80 (left column) and osteocalcin (right column) 825 
expression in serial sections of bone in WT mice or CD169-DTR (DTR) mice treated with 826 
vehicle (Veh) or DT. F4/80+ osteomac canopy structure (left column, red arrows) can be seen 827 
associated with osteocalcin+ osteoblasts (right column, black arrows) on endosteal diaphyseal 828 
cortical bone in all groups except for DT-treated CD169-DTR mice.  829 
Figure 3. Kinetics and quantification of bone and BM impacts of DT treatment in the 830 
CD169-DTR mouse model.  831 
A-D) Representative images of IHC staining (brown) for F4/80 (A and C) and Osteocalcin (B 832 
and D) expression in sagittal sections of the tibia. Paired images are serial sections representing 833 
the diaphyseal region of the tibia on Day 2 after a single DT injection (A and B) and on Day 4 834 
after 3 DT injections (C and D) in CD169-DTR mice. All sections were counterstained with 835 
hematoxylin. Crosshatch (#) demarks anatomical landmarks in paired serial sections. Original 836 
magnification is 20x. E-F) Quantification of percent of osteomac/bone surface (OM/BS [%]) (E) 837 
and osteoblast/bone surface (OB/BS [%] (F) on endosteum in WT or CD169-DTR (DTR) mice 838 
treated with vehicle (DTRx -) or DT (DTRx +). G) Quantification of the number of F4/80+ 839 
osteomacs per mm2 area of periosteum in WT or CD169-DTR (DTR) mice treated with vehicle 840 
(DTRx -) or DT (DTRx +). Each data point represents the mean of 3 independent measurements 841 
at 3 different sectional depths at least 50 µm apart. Significance was determined using one-way 842 
ANOVA with Tukey’s post-test. **, p<0.01; ***, p<0.001. Error bars represent standard 843 
deviation. 844 
Figure 4. DT treatment in CD169-DTR mice had no impact on TRAP staining features or 845 
osteoclasts frequency but increased serum TRAP activity.  846 
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A-D) Representative images of TRAP staining (magenta) in sagittal sections of bone in vehicle 847 
(Veh) or DT-treated WT (A and B, respectively) or CD169-DTR (DTR, C and D, respectively) 848 
mice. TRAP+ multinucleated osteoclasts are indicated by arrows. Original magnification: 20x 849 
(Ai-Di), 60x (Aii-Dii). Scale bar: 100 µm (Ai-Di), 20 µm (Aii-Dii). E-I) Quantification of 850 
percent length of TRAP surface (TRAP.S) per bone surface (BS) (E), percent area of TRAP 851 
staining within the metaphyseal region (F), TRAP staining intensity within the metaphyseal 852 
region (G), unit per liter (U/L) of serum TRAP-5b activity (H) and percent trabecular bone (Tb) 853 
area within the metaphyseal region (I) in vehicle (DTRx -) or DT-treated (DTRx +) WT mice or 854 
CD169-DTR mice (DTR). Significance was determined using one-way ANOVA with Tukey’s 855 
post-test. Each data point represents the mean of 3 independent measurements at 3 different 856 
sectional depths at least 50 µm apart. ***, p<0.001. Error bars represent standard deviation. 857 
Figure 5. CD169+ macrophage depletion reduced F4/80+ macrophage number within tibial 858 
bone injury associated granulation tissue.  859 
A) Schematic detailing the experimental design including timing of DT/vehicle injections and 860 
tissue/cell harvest relative to surgery (Tx). B-C) Flow cytometric quantification of F4/80+Ly6G- 861 
myeloid cell (B, F+G- cells) and F4/80+Ly6G-CD115lowCD169+ macrophage (C, CD169+ cells) 862 
number in femoral BM from vehicle or DT-treated CD169-DTR mice. D) Percent area of F4/80 863 
staining within the injury site of vehicle-treated (DTR-Vehicle) and DT-treated CD169-DTR 864 
(DTR-DT) mice. Each data point represents mean of 3 independent measurements per sample 865 
taken at different sectional depths at least 50 µm apart. Significance was determined using two-866 
tailed unpaired t-test. **, p<0.01; ***, p<0.001. Error bars represent standard deviation. E-F) 867 
Representative images of IHC staining for F4/80 expression (brown) in tibial injury sites in 868 
CD169-DTR mice treated with vehicle (DTR-Vehicle) or DT (DTR-DT). All sections were 869 
counterstained with hematoxylin. The bone injury site is demarked by the dotted black box.  870 
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Original magnification was 10x and scale bar indicates 200 µm. Abbreviations: CB, cortical 871 
bone; and BM, bone marrow. 872 
 Figure 6. CD169+ macrophage depletion reduced osteomacs and Col1a1+ woven bone 873 
deposition in tibial bone injury sites.  874 
A) Schematic detailing the experimental design including timing of DT/vehicle injection and 875 
tissue/cell harvest relative to surgery (TD). B-C) Flow cytometric quantification of F4/80+Ly6G-876 
CD115lowCD169+ macrophage (B, CD169+ cells) and F4/80+Ly6G- myeloid cell (C, F+G- cells) 877 
numbers in femoral BM from vehicle or DT-treated CD169-DTR mice. D-I) Representative 878 
images of IHC staining for F4/80 (D-E, G-H, brown) and Col1a1 (F and I, brown) expression in 879 
the tibial injury site of vehicle (D-F) or DT-treated (G-I) CD169-DTR mice. Osteomacs 880 
intercalated throughout woven bone are indicated by black arrows in E. Asterisks in D and G 881 
indicate injury adjacent BM. All sections were counterstained with hematoxylin. Original 882 
magnifications: 10x (D, G) and 40x (E, H). Scale bar represents 200 µm in D, G, F and I and 50 883 
µm in E and H. J) Percent area of F4/80 staining within the injury site of vehicle-treated and DT-884 
treated CD169-DTR mice. K) Percent area of Col1a1+ regenerative tissue and Col1a1+ fibrotic 885 
tissue within the injury site in vehicle-treated and DT-treated CD169-DTR mice. L) Percent 886 
length of osteoclast surface (Oc.S) per bone surface (BS) in the metaphyseal region of the injured 887 
limb. Each data point represents the mean of 3 independent measurements per sample taken in 888 
sections at least 50 µm apart. Significance was determined using two-tailed unpaired t-test (*, 889 
p<0.05 and ***, p<0.001). Error bars represent standard deviation 890 
Figure 7. CD169+ macrophage depletion reduced the number of galectin-3+ macrophages 891 
associated with intramembranous ossification in the tibial injury model.  892 
Representative images of dual immunofluorescence staining for F4/80 and galectin-3 expression 893 
within the injury site of vehicle-treated and DT-treated CD169-DTR mice (n = 3, experimental 894 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
40 
 
design as per Figure 6A). DAPI nuclear staining is pseudo-colored blue (all panels), F4/80 895 
expression is pseudo-colored red (left and middle panel) and galectin-3 expression is pseudo-896 
colored green (left and right panel). Co-localization is indicated by yellow in the merged image 897 
(right panel). Original magnification, 20x; scale bar represents 100 µm. 898 
Figure 8. CD169+ macrophage depletion initiated during the inflammatory phase of 899 
fracture repair significantly impaired callus formation.  900 
A) Schematic of the experimental design including timing of DT/vehicle injections and tissue 901 
harvest relative to surgery (Fx) as well as how these coincided with fracture healing phase 902 
progression [28]. B-C) Flow cytometric quantification of F4/80+Ly6G- myeloid cell (B, F+G- 903 
cells) and F4/80+Ly6G-CD115lowCD169+ macrophage (C, CD169+ cells) number in femoral BM 904 
from vehicle or DT-treated CD169-DTR mice. D-G) Representative images of the periosteal 905 
injury zone stained with Safranin-O (D-E) or for F4/80 expression (F-G) from vehicle-treated (D 906 
and F) or DT-treated (E and G) CD169-DTR mice. Black dotted lines in D indicate hard callus 907 
with soft callus stained red. Asterisk in G indicated BM adjacent to the injury site.  Black arrows 908 
indicate cortical fracture gap. Original magnification, x4 and scale bars indicate 200 µm. H) 909 
Quantification of the total callus area (mm2) in vehicle-treated or DT-treated mice. I) 910 
Quantification of number of F4/80+ cells per mm2 of granulation tissue and woven bone within 911 
the callus. Each data point represents mean of 3 independent measurements per sample taken at 912 
different sectional depths at least 50 µm apart. Significance in B, C, H and I was determined 913 
using two-tailed unpaired t-test (**, p<0.01; ***, p<0.001). Error bars represent standard 914 
deviation. J) Pearson correlation (r = 0.9, p<0.001) between number of F4/80+ cells within the 915 
callus and total callus size (mm2). 916 
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